Diagnostic and prognostic value of serum MACC1 in breast cancer patients

Metastasis-associated in colon cancer-1 (MACC1) promotes colorectal cancer progression and predicts prognosis. The aim of our study was to determine the diagnostic and prognostic value of preoperative serum MACC1 levels in breast cancer patients. Serum MACC1 levels were measured in 378 breast cancer...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-12, Vol.7 (51), p.84408-84415
Main Authors: Tan, Weige, Xie, Xinhua, Li, Laisheng, Tang, Hailin, Ye, Xigang, Chen, Lun, Tang, Wei, Gao, Jin, Pan, Lingxiao, Zhang, Xiaoshen, Ye, Feng, Li, Xing, Yang, Lu, Xie, Xiaoming, Zheng, Wenbo
Format: Article
Language:English
Subjects:
Adult
Biomarkers, Tumor - blood
Breast Neoplasms - blood
Breast Neoplasms - diagnosis
Breast Neoplasms - therapy
Disease-Free Survival
Humans
Lymphatic Metastasis
Middle Aged
Multivariate Analysis
Neoplasm Staging
Outcome Assessment (Health Care) - methods
Outcome Assessment (Health Care) - statistics & numerical data
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Research Paper
Transcription Factors - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metastasis-associated in colon cancer-1 (MACC1) promotes colorectal cancer progression and predicts prognosis. The aim of our study was to determine the diagnostic and prognostic value of preoperative serum MACC1 levels in breast cancer patients. Serum MACC1 levels were measured in 378 breast cancer patients, 120 patients with benign breast disease, and 40 healthy volunteers using an ELISA. Serum MACC1 levels were higher in breast cancer patients than patients with benign disease or healthy volunteers. Increased serum MACC1 was associated with breast cancer TNM stage (P < 0.001), tumor size (P < 0.001), lymph node metastasis (P < 0.001), and Ki-67 status (P = 0.014). Serum MACC1 measurement successfully discriminated breast cancer patients from normal and healthy controls (AUC = 0.785, 95% CI: 0.746-0.825) with an optimal cut-off value of 38.35 pg/ml (sensitivity = 0.725, specificity = 0.696). Moreover, serum MACC1 exhibited significant prognostic value in breast cancer (AUC = 0.757, 95% CI: 0.700-0.814), and high MACC1 was associated with poor disease-free survival (HR 5.63, 95% CI: 3.51-9.04; P < 0.001). Our findings demonstrated that circulating MACC1 could serve as a reliable diagnostic and prognostic biomarker for breast cancer.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.12910